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Recurrent chromosomal translocations have been identified in MALT lymphoma, 1 
including t(11;18)(q21;q21), t(14;18)(q32;q21), t(1;14)(p22;q32), and 2 
t(3;14)(p14;q32).[1] The former three translocations lead to the generation of the 3 
BIRC3-MALT1 chimeric protein or deregulated expression of MALT1 or BCL10 4 
under the control of the juxtaposed immunoglobulin heavy chain gene (IGH), 5 
and finally activate the nuclear-factor κB pathway.[1] t(X;14)(p11;q32) is the fifth 6 
translocation in MALT lymphoma involving the parotid gland or lung.[2, 3] The 7 
translocation results in the juxtaposition of the G protein-coupled receptor 8 
(GPCR) 34 (GPR34) gene at Xp11.4 to the IGH gene at 14q32, and 9 
t(X;14)-MALT lymphoma was found to have the highest GPR34 mRNA levels 10 
among B-cell lymphoma subtypes.[2] However, it remains unclear whether 11 
t(X;14) characterizes a subgroup of MALT lymphoma that shows a particular 12 
cytomorphology and clinical behavior. We herein describe two cases of MALT 13 
lymphoma that carried the t(X;14). 14 
The first case (case 1) was a 66-year-old female who presented with tumors 15 
within the left parotid gland. She had been diagnosed with Sjögren syndrome 16 
and immune thrombocytopenia 6 years earlier. Sjögren antibody SS-A/Ro index 17 
was 105 (reference value, <25.0), SS-B/La was 32 (<25.0), anti-nuclear antibody 18 
was ×160 (<×40.0), and rheumatoid factor (RF) was 16.9 IU/mL. Although no 19 
residual tumor was detected after superficial lobectomy of the parotid gland, she 20 
relapsed 6.5 years after the initial presentation; the disease involved the left 21 
palatine tonsil and ileocecum with regional lymph nodes (Supplementary Figure 22 
S1A). She received 6 cycles of chemotherapy consisting of rituximab, 23 
cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), 24 
MALT lymphoma with t(X;14)(p11;q32)  Akasaka T et al. 
3 
 
leading to a complete response. The second cases (case 2) was a 66-year-old 1 
male who presented with symmetric enlargement of the bilateral parotid glands 2 
(Supplementary Figure S1B). He had been treated for rheumatoid arthritis with 3 
prednisolone and methotrexate followed by intravenous tocilizumab. His lactate 4 
dehydrogenase (LDH) level was 265 IU/L, soluble interleukin-2 receptor (IL-2R) 5 
was 2,037 U/mL, RF was 519.9 IU/mL, and matrix metalloproteinase-3 was 6 
218.7 ng/dL (reference range, 36.9 to 121). He was treated with 6 cycles of 7 
R-CHOP, excluding prednisolone because of seropositivity for the hepatitis B 8 
virus surface antigen, and achieved a complete response. Informed consent was 9 
obtained from the patients. This study was approved by the Institutional Review 10 
Board. 11 
Examination of histopathological specimens obtained from the parotid gland 12 
disclosed salivary gland tissues diffusely infiltrated by CD20+ lymphoma cells, 13 
and groups of these cells infiltrated into the glandular epithelium to generate the 14 
lymphoepithelial appearance (Supplementary Figure S2). The cells were 15 
medium to large in size with a moderate amount of cytoplasm, and CD79a+, 16 
BCL2+, CD5−, CD10−, and cyclin D1−. The Ki-67 proliferation index was 17 
approximately 50%. The cell surface immunoglobulins were µ-heavy and κ-light 18 
chains, and the δ-heavy chain was expressed at low levels (Supplementary 19 
Figures S3 and S4). 20 
G-banding of metaphase spreads obtained from the specimens revealed the 21 
t(X;14)(p11;q32) in both cases, and fluorescence in situ hybridization using the 22 
IGH break-apart probe confirmed the translocation. Karyotypes according to the 23 
ISCN (2013) were 47,X,t(X;14)(p11;q32),+18,add(22)(p11)[9]/46,XX[1] in case 1 24 
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and 47,Y,t(X;14)(p11;q32),+21[8]/46,XY[2] in case 2 (Supplementary Figure S5).  1 
To clone the t(X;14)(p11;q32) junction, we designed primers for the Cα 2 
constant gene of IGH and for the upstream sequence of the GPR82 gene, which 3 
is another GPCR gene and is localized 27-kb downstream of GPR34 (Figure 1A). 4 
Genomic DNA from the biopsies was subjected to long-distance polymerase 5 
chain reaction (LD-PCR) under the conditions for a long DNA target, resulting in 6 
the amplification of 3.6 and 6.0-kb of DNA, respectively (Figure 1B). We then 7 
cloned the LD-PCR products into the plasmid and performed Sanger sequencing 8 
(Figure 1C). Breakpoints were located at intron 1 (case 1) and the coding region 9 
of GPR82 (case 2), and those at the IGH gene were within the switch region 10 
associated with IGH Cα2. As a result of translocation, GPR34 and IGH Cα2 11 
were aligned in the same transcriptional orientation (Figure 1A). 12 
We next performed reverse-transcriptase (RT-) PCR to investigate the mRNA 13 
levels of GPR34 and GPR82, the expression of which delineates a unique 14 
molecular subset of marginal zone lymphoma.[2] As shown in Figure 1D, the 15 
level of GPR34 mRNA in case 1 was significantly higher than those in various 16 
hematological tumor cell lines. On the other hand, the expression of GPR82 17 
mRNA was detected in case 1, while similar levels of RT-PCR products were 18 
generated in cell lines from B-cell precursor leukemia, follicular lymphoma, and 19 
Burkitt lymphoma. Since t(X;14) disrupted the genomic structure of GPR82 and 20 
the primers were designed for exons 1 and 3 (Figure 1A), GPR82 mRNA 21 
expression in case 1 theoretically represented the transcriptional activity of the 22 
non-translocated homologue at normal chromosome X. 23 
We finally isolated the VH-DH-JH sequences in the current two cases in 24 
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addition to the Mayo clinic case by the inverse PCR strategy to characterize the 1 
IGH repertoire in t(X;14)-MALT lymphoma (Supplementary Table SI). In the 3 2 
cases, DNA fragments including the entire length of the VH-DH-JH segments were 3 
successfully amplified, and nucleotide sequencing revealed a single VH-DH-JH 4 
rearrangement in frame without stop codons. The closest germline VH, DH, and 5 
JH genes were identified in each case and the sequence identities of the VH 6 
genes were 95.1%, 86.5%, and 96.5%, respectively, providing evidence for a 7 
somatic hypermutation (Table I). We then calculated the excess of replacement 8 
(R) mutations over silent (S) mutations in the complementarity determining 9 
regions (CDRs) and the scarcity of R mutations in the framework regions 10 
(FWRs). As shown in Table I, we found no preferential clustering of R mutations 11 
indicative of positive selection in CDRs, while a decrease in R mutations in 12 
FWRs was found in all cases and negative selection in the Mayo clinic case was 13 
significant with a P value of <0.05.[4, 5] The CDR3 sequences of the 3 cases 14 
were characterized by the GC-rich alignment, particularly in the N sequences, 15 
and the CDR3 length was 17 or 16 at the amino acid level (Supplementary Table 16 
SII). A database search revealed a similarity of the CDR3 sequence of cases 1 17 
with that of an IgM RF derived from healthy immunized donors (Supplementary 18 
Table SIII). 19 
In line with the general concept of the development of MALT lymphoma, both 20 
patients had chronic autoimmune disorders and showed serological evidence of 21 
each underlying disease at presentation. By comparison with the typical MALT 22 
lymphoma cytomorphology, lymphoma cells in the current two cases were larger 23 
and had rounder nuclear contours, more vesicular chromatin, and more 24 
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conspicuous nucleoli, representing the features of diffuse large B-cell lymphoma 1 
(DLBCL). Nevertheless, marginal zone infiltrates of reactive follicles and 2 
lymphoepithelial lesions were in agreement with the histopathological criteria of 3 
MALT lymphoma. On the other hand, the palatine tonsil and ileocecum involved 4 
in case 1 at relapse are unusual sites of involvement of MALT lymphoma, but 5 
preferentially affected by DLBCL. In case 2, the marked enlargement of both 6 
parotid glands and elevated LDH and sIL-2R levels initially indicated aggressive 7 
lymphoma. Therefore, the current two cases appear to be characterized by 8 
intermediate features in cytomorphology and clinical behavior between 9 
low-grade MALT lymphoma and DLBCL. 10 
GPR34 is the first GPCR gene that is affected by chromosomal translocation 11 
in B-cell tumors. Since potent enhancer complexes are localized downstream of 12 
the two IGH Cα genes,[6] and since t(X;14) does not interrupt the coding region 13 
of GPR34, t(X;14) theoretically promotes the expression of GPR34, and we 14 
confirmed the strong expression of GPR34 mRNA in case 1. GPCRs, including 15 
class A GPR34, are integral membrane proteins containing 7 putative 16 
transmembrane domains and mediate signals to the interior of the cell via the 17 
activation of heterotrimeric G proteins. A large number of GPCRs are 18 
overexpressed in various cancer types, and contribute to tumor cell growth when 19 
activated by circulating or locally produced ligands.[7] Lysophosphatidylserine, 20 
which is an endogenous lipid mediator generated by the hydrolysis of the 21 
membrane phospholipid phosphatidylserine, has been proposed to be the ligand 22 
of GPR34.[8] Since the current two cases developed in the setting of chronic 23 
autoimmune disorders, the potential link between the underlying inflammatory 24 
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disease and occurrence of lymphoma may be attributed to ligands being steadily 1 
generated in salivary gland tissues affected by chronic inflammation, which, in 2 
turn, stimulate GPR34-overexpressing cells resulting from t(X;14), thereby 3 
leading to the development of florid lymphoma.  4 
We showed that VH genes were variable among the 3 cases. Of the 3 VH 5 
genes, VH1-2 has been reported to be preferentially used in splenic marginal 6 
zone lymphoma,[9] while its usage is infrequent in MALT lymphoma that 7 
develops in the stomach, lung, and parotid gland.[10-12] In contrast, VH1-69 is 8 
involved in not only cases of B-cell chronic lymphocytic leukemia, but also 9 
salivary gland MALT lymphoma at a frequency of 8 of 14 (57%).[13, 14] VH3-7 10 
appears to be preferentially used in gastric MALT lymphoma.[10-12] On the 11 
other hand, a statistical analysis of the distribution of R and S mutations within 12 
CDRs or FWRs provided no significant evidence for antigen selection, whereas 13 
negative selection for R mutations in FWRs in order to maintain the configuration 14 
of the IGH molecule appeared to have been operating. Taken together with the 15 
long CDR3 length, t(X;14)-MALT lymphoma may arise from B cells that 16 
recognize self-antigens.[15] 17 
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Figure legends 1 
 2 
Figure 1. Molecular cloning of the t(X;14)(p11;q32)/GPR34-IGH junction. (A) 3 
Schematic presentation of the anatomy of t(X;14)(p11;q32). The coding exons of 4 
GPR34 and GPR82 are intron-less (rectangles filled with black). Breakpoints in 5 
case 1 and case 2 (open triangle) as well as that in the Mayo clinic case (closed 6 
triangle) [2] are distributed within the GPR82 gene. (B) Ethidium bromide-stained 7 
gel electrophoresis of LD-PCR encompassing the t(X14)(p11;q32) junction. The 8 
positions of the primers for LD-PCR are indicated in A. (C) Nucleotide 9 
sequences of the t(X;14)(p11;q32) junction in case 1 and case 2. Vertical lines 10 
indicate nucleotide identity. (D) RT-PCR for the expression of GPR34 and 11 
GPR82 mRNA. The hematological tumor cell lines used were: ME-1, acute 12 
myeloid leukemia; CCRF-CEM, T-cell acute lymphoblastic leukemia; NALM-20 13 
and NALM-6, B-cell precursor leukemia; SMZ-1, peripheral T-cell lymphoma; 14 
Karpas299, anaplastic large cell lymphoma; KM-H2 and L428, Hodgkin 15 
lymphoma; FL-318 and FL-218, follicular lymphoma; and Ramos and Raji, 16 
Burkitt lymphoma. RT-PCR for GAPDH is shown in the bottom to confirm that 17 
similar amounts of mRNA were loaded. The sequences of the primers for LD- 18 
and RT-PCR are described in Supplementary Table SI. 19 
 20 
IGHA-01 primer 
Cα2 Sα 
Xp11-05 primer 
GPR34 GPR82 
27 kb 
Cα2 GPR34 
Case 1 Case 2 
Xp11.4 
14q32 
Case 1 
der(14)t(X;14) Sα 
A 
Xp11.4  AGTATTTTTAAACCCATTTTTTATGTTCTACACCAAAGAGATAACTGTCAGCAATTGAATTATTTAATAG 
        ||||||||||||||||||||||||||||||||||   ||| |         |                || 
Case 2  AGTATTTTTAAACCCATTTTTTATGTTCTACACCGGTGAGCTGGACTGGGCCGGGCTGGGCTGAGCTGAG 
              |         |    |  | |   |   | |||||||||||||||||||||||||||||||||| 
Salpha2 CTGGACTGGGCTAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGGACTGGGCCGGGCTGGGCTGAGCTGAG 
Xp11.4  GTTTTTAGTATACTATGCATTATCTGCACAAGGTAGGAGCTACTGCTTTTCTTTAACAGCATCATAAAAG 
        ||||||||||||||||||||||||||||| |  | ||     ||   ||    |        |        
Case 1  GTTTTTAGTATACTATGCATTATCTGCACCAACTGGGCTGGGCTAGATTGGGCTGGGCTGGACTGGGCTG 
        |  |    |   ||  ||       |    | |||||||||||||||||||||||||||||||||||||| 
Salpha2 GACTGGGCTGGGCTGGGCTGGGCTGGGCTGAGCTGGGCTGGGCTAGATTGGGCTGGGCTGGACTGGGCTG 
10 –  
5 –  
2 –  
kb 
300 – 
100 – 
200 – 
500 – 
500 – 
300 – 
300 – 
GPR34 
GPR82 
GAPDH 
bp 
B 
C 
D 
Table I. Somatic mutation analysis of the IGH gene in MALT lymphomas with t(X;14)(p11;q32) 
Case VH gene % 
identity 
Observed mutations Expected  Focused test* 
CDR FWR CDR FWR Selection value (Σ) P-value** 
R S R S R S R S CDR FWR CDR FWR 
Case 1 VH3-7 95.1% 4 1 5 4 0.2 0.05 0.56 0.2 0.00553 −0.823 0.492 −0.0872 
Case 2 VH1-2 86.5% 5 2 20 12 0.14 0.05 0.61 0.2 −0.38 −0.547 −0.227 −0.0571 
Mayo 
clinic 
case 
VH1-69 96.5% 2 1 2 5 0.17 0.06 0.57 0.21 −0.543 −1.77 −0.240 −0.0059 
Abbreviations: R, replacement; S, silent; CDR, complementarity determining region; FWR, framework region. 
*Σ and P values were calculated using the Focused-Z test to detect selection.[4, 5] 
**A negative sign indicates negative selection. P values < 0.05 were considered to be significant. 
 
